Business Context and Reporting Period
Company: Humacyte, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 10, 2026
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics related to the transaction include:
- Shares to be Issued (Firm): 47,619,048 shares of common stock.
- Offering Price: $1.05 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 7,142,857 additional shares.
- Expected Net Proceeds (Base): Approximately $46.80 million (after underwriting discounts and estimated expenses).
- Expected Net Proceeds (With Full Option): Approximately $53.85 million.
- Expected Closing Date: On or about June 12, 2026.
Note: The filing text does not provide current revenue, profit, cash flow, margins, or debt levels. Investors should refer to the Company's most recent 10-K or 10-Q for operational financials.
Material Changes
The primary material change is the dilution of existing shareholders due to the issuance of new shares and the anticipated increase in the Company's cash liquidity upon closing of the offering. The filing does not provide comparative period data for operational metrics.
Guidance, Outlook, and Risks
Management Commentary: The Company entered into an underwriting agreement with Barclays Capital Inc., BTIG, LLC, and Titan Partners Group LLC. The offering is made pursuant to an effective shelf registration statement (Form S-3) filed in September 2025.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
- Legal Disclaimer: Representations and warranties in the Underwriting Agreement are not intended as factual information for the public; investors should rely on other SEC filings.
- Regulation FD: Press releases regarding the pricing and commencement of the offering are furnished but not deemed "filed" for Section 18 liability purposes.
Investor Verification Checklist
- Verify the final closing date and whether the underwriters exercised the 30-day over-allotment option.
- Review the Company's most recent 10-K or 10-Q to assess current cash runway and burn rate relative to the new proceeds.
- Confirm the exact amount of underwriting discounts and commissions deducted from the gross proceeds.
- Check for any subsequent filings regarding the use of proceeds or changes in the Company's capital structure.